Figure 3.

Thrombin does not activate TEM. (A) GPNT or primary BMVECs and PAS were pre-treated for 1 h with Hirudin (20 U/mL) and then combined for 4 h TEM assays. (B) GPNT were pre-treated for 1h with the indicated concentrations of thrombin or the PAR-1 TFLLR agonist before PAS were added and 4 h TEM assessed. Data represented as normalised means −/+ SEM. Each data point represents one independent, biological replicate. Significant differences from controls were determined ANOVA and Dunnett’s post-hoc analysis with ** p < 0.01 (vs. control).